JACKSONVILLE, Florida, November 30, 2015 /PRNewswire/ --

TapImmune, Inc. [http://www.tapimmune.com ] (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 8th Annual LD Micro Main Event on December 1, 2015 at 2.30 PM PT. Dr. John N. Bonfiglio a TapImmune Board member and Strategic Advisor will be giving the presentation and will join TapImmune management in meeting with investors.

The conference will be held at the Luxe Sunset Bel Air Hotel, Los Angeles, CA, and will feature 210 companies in the small/micro-cap space. To view a webcast of the presentation please visit:  

http://wsw.com/webcast/ldmicro9/tpiv

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit http://www.ldmicro.com .

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements. 


        
         
        CONTACTS: 
        TapImmune Inc., 
        Glynn Wilson, Ph.D. 
        Chairman & CEO 
        +1-866-359-7541 

 

SOURCE TapImmune Inc.